PL2058317T3 - Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny - Google Patents

Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny

Info

Publication number: PL2058317T3
Authority: PL; Poland
Prior art keywords: active ingredient; acid ester; same; ester derivative; receptor modulator
Prior art date: 2006-08-08

Application number

PL07792066T

Other languages

English (en)

Inventor

Yasushi Kohno

Kiyoshi Fujii

Tatsuhiro Saito

Original Assignee

Kyorin Seiyaku Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-08

Filing date

2007-08-07

Publication date

2014-03-31

2007-08-07 Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk

2014-03-31 Publication of PL2058317T3 publication Critical patent/PL2058317T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)

PL07792066T 2006-08-08 2007-08-07 Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny PL2058317T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006215280		2006-08-08
PCT/JP2007/065397 WO2008018427A1 (en)	2006-08-08	2007-08-07	Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
EP07792066.8A EP2058317B1 (en)	2006-08-08	2007-08-07	Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient

Publications (1)

Publication Number	Publication Date
PL2058317T3 true PL2058317T3 (pl)	2014-03-31

Family

ID=39032957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07792066T PL2058317T3 (pl)	2006-08-08	2007-08-07	Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny

Country Status (26)

Country	Link
US (1)	US8232319B2 (pl)
EP (1)	EP2058317B1 (pl)
JP (1)	JP5188972B2 (pl)
KR (1)	KR101339976B1 (pl)
CN (1)	CN101501049B (pl)
CA (1)	CA2659598A1 (pl)
CY (1)	CY1114681T1 (pl)
DK (1)	DK2058317T3 (pl)
ES (1)	ES2438265T3 (pl)
HR (1)	HRP20131172T1 (pl)
IL (1)	IL196275A (pl)
MA (1)	MA30663B1 (pl)
ME (1)	ME02095B (pl)
MX (1)	MX2009001456A (pl)
MY (1)	MY152176A (pl)
NO (1)	NO20090606L (pl)
NZ (1)	NZ574011A (pl)
PL (1)	PL2058317T3 (pl)
PT (1)	PT2058317E (pl)
RS (1)	RS53080B (pl)
RU (1)	RU2430925C2 (pl)
SG (1)	SG174028A1 (pl)
SI (1)	SI2058317T1 (pl)
TN (1)	TNSN08545A1 (pl)
WO (1)	WO2008018427A1 (pl)
ZA (1)	ZA200900206B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009099174A1 (ja)	2008-02-07	2009-08-13	Kyorin Pharmaceutical Co., Ltd.	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
WO2009142194A1 (ja) *	2008-05-19	2009-11-26	杏林製薬株式会社	光学活性アミノアルコール誘導体の製造方法
TW201000109A (en) *	2008-05-20	2010-01-01	Kyorin Seiyaku Kk	Agent for induction/maintenance of remission
SI2326621T1 (sl)	2008-07-23	2016-10-28	Arena Pharmaceuticals, Inc.	Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj
NZ591001A (en)	2008-08-27	2012-11-30	Arena Pharm Inc	Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
PL2452944T3 (pl)	2009-07-09	2015-03-31	Kyorin Seiyaku Kk	Pochodne difenylosiarczkowe i leki je zawierające jako składniki aktywne
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
TWI519539B (zh)	2010-12-21	2016-02-01	Kyorin Seiyaku Kk	Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
EP2699549A1 (en) *	2011-04-18	2014-02-26	Allergan, Inc.	Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
CN102863345A (zh) *	2011-07-06	2013-01-09	中国医学科学院药物研究所	胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2015194157A1 (ja) *	2014-06-16	2015-12-23	杏林製薬株式会社	ジフェニルスルフィド誘導体の製造方法及び製造中間体
CN116850181A (zh)	2015-01-06	2023-10-10	艾尼纳制药公司	治疗与s1p1受体有关的病症的方法
AU2016284162A1 (en)	2015-06-22	2018-02-01	Arena Pharmaceuticals, Inc.	Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
WO2017214234A1 (en)	2016-06-07	2017-12-14	Tesla, Inc.	Electric motor waste heat mode to heat battery
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US10967702B2 (en)	2017-09-07	2021-04-06	Tesla, Inc.	Optimal source electric vehicle heat pump with extreme temperature heating capability and efficient thermal preconditioning
WO2019236757A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
US11555015B2 (en)	2018-09-06	2023-01-17	Arena Pharmaceuticals, Inc.	Compounds useful in the treatment of autoimmune and inflammatory disorders
MX2021010217A (es)	2019-02-26	2021-09-21	Bayer Ag	Derivados heterociclos biciclicos condensados como plaguicida.
US20230398099A1 (en) *	2020-11-09	2023-12-14	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
US11932078B2 (en)	2021-03-31	2024-03-19	Tesla, Inc.	Electric vehicle heat pump using enhanced valve unit

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444766A (en) *	1980-10-21	1984-04-24	Boehringer Mannheim Gmbh	Sulfur-containing phospholipid compounds and therapeutic compositions
US5604229A (en)	1992-10-21	1997-02-18	Yoshitomi Pharmaceutical Industries, Ltd.	2-amino-1,3-propanediol compound and immunosuppressant
US5948820A (en)	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
US5447922A (en)	1994-08-24	1995-09-05	Bristol-Myers Squibb Company	α-phosphonosulfinic squalene synthetase inhibitors
SI1319651T1 (en)	1997-04-04	2005-10-31	Mitsubishi Pharma Corporation	2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
WO2000001388A1 (en)	1998-07-02	2000-01-13	Kyowa Hakko Kogyo Co., Ltd.	Remedies for diabetes
AU767241B2 (en)	1998-09-14	2003-11-06	Qiang Xu	Immunosuppressive agents
US20020143034A1 (en)	1998-12-30	2002-10-03	Fujisawa Pharmaceutical Co. Ltd.	Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (en)	2000-06-20	2001-12-27	Japan Tobacco Inc.	Pyrazolopyridine compounds and use thereof as drugs
SK152003A3 (en)	2000-07-13	2004-07-07	Sankyo Co	Amino alcohol derivatives
JP2002053575A (ja)	2000-08-09	2002-02-19	Sankyo Co Ltd	アミノアルコ−ル類
WO2002018395A1 (en)	2000-08-31	2002-03-07	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
EP1383778B1 (en)	2001-01-30	2009-10-21	University Of Virginia Patent Foundation	Agonists and antagonists of sphingosine-1-phosphate receptors
DE60234318D1 (de)	2001-02-08	2009-12-24	Ono Pharmaceutical Co	Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ES2267993T3 (es)	2001-02-22	2007-03-16	Novartis Ag	Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto.
IL157773A0 (en)	2001-03-26	2004-03-28	Novartis Ag	2-amino-propanol derivatives
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
ES2316613T3 (es)	2001-05-10	2009-04-16	Ono Pharmaceutical Co., Ltd.	Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
US20040138462A1 (en)	2001-05-24	2004-07-15	Minoru Sakurai	Aminoalcohol derivatives
US20040235794A1 (en)	2001-09-04	2004-11-25	Shinji Nakade	Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029184A1 (en)	2001-09-27	2003-04-10	Kyorin Pharmaceutical Co., Ltd.	Diaryl ether derivative, addition salt thereof, and immunosuppressant
CN1329372C (zh)	2001-09-27	2007-08-01	杏林制药株式会社	二芳基硫醚衍生物及其加成盐和免疫抑制剂
JP4035759B2 (ja)	2001-11-06	2008-01-23	独立行政法人産業技術総合研究所	アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005112721A (ja)	2001-11-06	2005-04-28	Maruha Corp	含窒素化合物、製造法、及びその利用方法
AU2002354476A1 (en)	2001-12-14	2003-06-30	Japan Tobacco Inc.	Pyrazolopyridine derivatives and medicinal use thereof
KR100836547B1 (ko)	2002-01-11	2008-06-10	상꾜 가부시키가이샤	아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
JP4771511B2 (ja)	2003-07-08	2011-09-14	第一三共株式会社	アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
JP2003267936A (ja)	2002-01-11	2003-09-25	Sankyo Co Ltd	ベンゼン環化合物
WO2003062252A1 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Edg receptor agonists
CA2472680A1 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Selective s1p1/edg1 receptor agonists
US20040058894A1 (en)	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
WO2003062248A2 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
AU2003217764A1 (en)	2002-03-01	2003-09-16	Merck & Co., Inc.	Aminoalkylphosphonates and related compounds as edg receptor agonists
AU2003218056A1 (en)	2002-03-01	2003-09-16	Merck & Co., Inc.	Aminoalkylphosphonates and related compounds as edg receptor agonists
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004002531A1 (ja)	2002-06-26	2004-01-08	Ono Pharmaceutical Co., Ltd.	血管の収縮または拡張による疾患治療剤
AU2003259296A1 (en)	2002-07-30	2004-02-16	University Of Virginia Patent Foundation	Compounds active in spinigosine 1-phosphate signaling
BR0314113A (pt)	2002-09-13	2005-07-12	Novartis Ag	Derivados de amino propanol
KR101003877B1 (ko)	2002-09-19	2010-12-30	교린 세이야꾸 가부시키 가이샤	아미노알코올 유도체와 그 부가염 및 면역 억제제
CN102526079B (zh)	2002-09-24	2014-06-18	诺华股份有限公司	治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
EP1553075B1 (en)	2002-10-03	2013-08-14	Ono Pharmaceutical Co., Ltd.	Lpa receptor antagonists
JP4140698B2 (ja)	2002-10-18	2008-08-27	第一三共株式会社	リン酸又はホスホン酸誘導体
CA2509218C (en)	2002-12-20	2010-09-07	Merck & Co., Inc.	1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists
EP1594508B1 (en)	2003-02-11	2012-08-08	Irm Llc	Novel bicyclic compounds and compositions
EP1602660B1 (en)	2003-02-18	2011-04-06	Kyorin Pharmaceutical Co., Ltd.	Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators
JP2004307439A (ja)	2003-04-10	2004-11-04	Kyorin Pharmaceut Co Ltd	アミノジオール誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja)	2003-04-10	2004-11-04	Kyorin Pharmaceut Co Ltd	２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307441A (ja)	2003-04-10	2004-11-04	Kyorin Pharmaceut Co Ltd	ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307442A (ja)	2003-04-10	2004-11-04	Kyorin Pharmaceut Co Ltd	ヘテロ環誘導体とその付加塩及び免疫抑制剤
MXPA05011597A (es)	2003-04-30	2005-12-15	Novartis Ag	Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
AU2004234066B2 (en)	2003-04-30	2008-02-21	Novartis Ag	Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
CN1788008A (zh)	2003-05-15	2006-06-14	麦克公司	作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
AU2004249664A1 (en)	2003-05-19	2004-12-29	Irm Llc	Immunosuppressant compounds and compositions
AU2004240649A1 (en)	2003-05-19	2004-12-02	Irm, Llc	Immunosuppressant compounds and compositions
GB0313612D0 (en)	2003-06-12	2003-07-16	Novartis Ag	Organic compounds
JP2005047899A (ja)	2003-07-11	2005-02-24	Sankyo Co Ltd	アミノアルコール化合物
WO2005014603A1 (en)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Phosphinane compounds with immunomodulating activity
WO2005014525A2 (en)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
BRPI0413151A (pt)	2003-08-28	2006-10-03	Novartis Ag	derivados de amino propanol
CN1874991A (zh)	2003-08-29	2006-12-06	小野药品工业株式会社	能够结合s1p受体的化合物及其药物用途
AU2004277947A1 (en)	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
GB0324210D0 (en)	2003-10-15	2003-11-19	Novartis Ag	Organic compounds
WO2005041899A2 (en)	2003-11-03	2005-05-12	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005044780A1 (ja)	2003-11-10	2005-05-19	Kyorin Pharmaceutical Co., Ltd.	アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
WO2005058848A1 (en)	2003-12-17	2005-06-30	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
TW200526548A (en)	2003-12-25	2005-08-16	Sankyo Co	Ether derivatives
GB0401332D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
WO2005082841A1 (en)	2004-02-24	2005-09-09	Irm Llc	Immunosuppressant compounds and compositions
NZ549162A (en)	2004-02-24	2009-12-24	Sankyo Co	Amino-pyrrol alcohol compounds
TW200538433A (en)	2004-02-24	2005-12-01	Irm Llc	Immunosuppressant compounds and compositiions
JP2005247691A (ja)	2004-03-01	2005-09-15	Toa Eiyo Ltd	Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en)	2004-03-09	2004-04-21	Novartis Ag	Organic compounds
GB0411929D0 (en)	2004-05-27	2004-06-30	Novartis Ag	Organic compounds
US8039674B2 (en)	2004-06-23	2011-10-18	Ono Pharmaceutical Co., Ltd.	Compound having S1P receptor binding potency and use thereof
PT1772145E (pt)	2004-07-16	2011-05-27	Kyorin Seiyaku Kk	Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios
TW200611687A (en)	2004-07-29	2006-04-16	Sankyo Co	Pharmaceutical compositions used for immunosuppressant
EP1781595A1 (en)	2004-08-13	2007-05-09	Praecis Pharmaceuticals Inc.	Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
BRPI0516337A (pt)	2004-10-12	2008-04-29	Kyorin Seiyaku Kk	processo para a produção de 2- amino-2-[4-(3-benziloxifeniltio) -2- (clorofenil} etil] - 1,3 - hidrocloreto de propanediol e hidratos dos mesmos e produtos intermerdiários para a produção dos mesmos
WO2006041015A1 (ja)	2004-10-12	2006-04-20	Kyorin Pharmaceutical Co., Ltd.	アミノアルコール誘導体とその付加塩及び免疫抑制剤
MX2007006706A (es)	2004-12-06	2007-10-18	Univ Virginia	Analogos de esfingosina 1-fosfato amida de arilo.
TW200702326A (en)	2005-05-31	2007-01-16	Mitsubishi Pharma Corp	2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh)	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途
MX2008003170A (es)	2005-09-09	2008-03-18	Novartis Ag	Tratamiento de enfermedades autoinmunes.
PL1932522T3 (pl)	2005-10-07	2012-09-28	Kyorin Seiyaku Kk	Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
US8546452B2 (en)	2005-10-12	2013-10-01	Toa Eiyo Ltd.	S1P3 receptor antagonist
TWI389683B (zh)	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8114902B2 (en)	2006-04-28	2012-02-14	Mitsubishi Tanabe Pharma Corporation	2-aminobutanol compound and use thereof for medical purposes
CN101505744A (zh)	2006-07-25	2009-08-12	爱尔康研究有限公司	用于预防和治疗眼部病症的内皮分化基因亚家庭3（edg-3，s1p3）受体的拮抗剂
US7877152B2 (en)	2006-07-31	2011-01-25	JusJas LLC	Bipolar stimulation/recording device with widely spaced electrodes

2007
- 2007-08-07 EP EP07792066.8A patent/EP2058317B1/en active Active
- 2007-08-07 PT PT77920668T patent/PT2058317E/pt unknown
- 2007-08-07 MY MYPI20085394 patent/MY152176A/en unknown
- 2007-08-07 RS RS20130551A patent/RS53080B/sr unknown
- 2007-08-07 CA CA002659598A patent/CA2659598A1/en not_active Abandoned
- 2007-08-07 US US12/310,007 patent/US8232319B2/en not_active Expired - Fee Related
- 2007-08-07 ME MEP-2013-551A patent/ME02095B/me unknown
- 2007-08-07 ES ES07792066.8T patent/ES2438265T3/es active Active
- 2007-08-07 MX MX2009001456A patent/MX2009001456A/es active IP Right Grant
- 2007-08-07 SG SG2011055589A patent/SG174028A1/en unknown
- 2007-08-07 NZ NZ574011A patent/NZ574011A/en not_active IP Right Cessation
- 2007-08-07 CN CN2007800295082A patent/CN101501049B/zh not_active Expired - Fee Related
- 2007-08-07 KR KR1020097004756A patent/KR101339976B1/ko not_active Expired - Fee Related
- 2007-08-07 HR HRP20131172TT patent/HRP20131172T1/hr unknown
- 2007-08-07 WO PCT/JP2007/065397 patent/WO2008018427A1/ja not_active Ceased
- 2007-08-07 RU RU2009106934/04A patent/RU2430925C2/ru not_active IP Right Cessation
- 2007-08-07 JP JP2008528818A patent/JP5188972B2/ja not_active Expired - Fee Related
- 2007-08-07 DK DK07792066.8T patent/DK2058317T3/da active
- 2007-08-07 PL PL07792066T patent/PL2058317T3/pl unknown
- 2007-08-07 SI SI200731372T patent/SI2058317T1/sl unknown
2008
- 2008-12-30 IL IL196275A patent/IL196275A/en not_active IP Right Cessation
- 2008-12-31 TN TNP2008000545A patent/TNSN08545A1/en unknown
2009
- 2009-01-09 ZA ZA200900206A patent/ZA200900206B/xx unknown
- 2009-02-10 NO NO20090606A patent/NO20090606L/no not_active Application Discontinuation
- 2009-02-26 MA MA31663A patent/MA30663B1/fr unknown
2013
- 2013-11-28 CY CY20131101071T patent/CY1114681T1/el unknown

Also Published As

Publication number	Publication date
RS53080B (sr)	2014-06-30
HK1131154A1 (en)	2010-01-15
ZA200900206B (en)	2009-12-30
SG174028A1 (en)	2011-09-29
MA30663B1 (fr)	2009-08-03
NZ574011A (en)	2011-10-28
DK2058317T3 (da)	2014-01-06
IL196275A (en)	2013-10-31
US20090325907A1 (en)	2009-12-31
MY152176A (en)	2014-08-15
JP5188972B2 (ja)	2013-04-24
TNSN08545A1 (en)	2010-04-14
ES2438265T3 (es)	2014-01-16
AU2007282536A1 (en)	2008-02-14
MX2009001456A (es)	2009-02-19
EP2058317B1 (en)	2013-10-16
KR20090046929A (ko)	2009-05-11
IL196275A0 (en)	2009-09-22
SI2058317T1 (sl)	2014-01-31
EP2058317A1 (en)	2009-05-13
NO20090606L (no)	2009-03-03
RU2430925C2 (ru)	2011-10-10
KR101339976B1 (ko)	2013-12-10
CY1114681T1 (el)	2016-10-05
ME02095B (en)	2014-06-30
CA2659598A1 (en)	2008-02-14
PT2058317E (pt)	2013-12-11
JPWO2008018427A1 (ja)	2009-12-24
CN101501049A (zh)	2009-08-05
HRP20131172T1 (hr)	2014-01-17
RU2009106934A (ru)	2010-09-20
US8232319B2 (en)	2012-07-31
WO2008018427A1 (en)	2008-02-14
EP2058317A4 (en)	2011-06-29
CN101501049B (zh)	2013-04-24

Publication	Publication Date	Title
ZA200900206B (en)	2009-12-30	Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient
HUS1800043I1 (hu)	2018-11-28	514 számú gyógyszerkészítmény
IL202473A (en)	2015-07-30	Carboxylic acids are converted to benzoylamino-indene-2, their compounds and medical preparations containing these acids
IL194954A0 (en)	2009-08-03	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2045253A4 (en)	2013-01-23	alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
IL196169A0 (en)	2009-09-22	Bile acid derivatives and pharmaceutical compositions containing the same
AP2008004671A0 (en)	2008-12-31	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
IL209054A0 (en)	2011-01-31	Solid pharmaceutical formulations comprising bibw 2992
SI3103448T1 (sl)	2019-11-29	Farmacevtski sestavek, ki vsebuje modulator S1P
EP2220081A4 (en)	2011-08-24	GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES
IL198513A0 (en)	2010-02-17	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
ZA200807354B (en)	2008-11-26	Dividable galenical form allowing modified release of the active ingredient
EP2266626A4 (en)	2012-10-17	COMPOSITION FOR TOPICAL APPLICATION WITH A TRANSCRIPTION FACTOR DECOY AS AN ACTIVE SUBSTANCE
IL201465A0 (en)	2010-05-31	Self-precipitating pharmaceutical formulations for the modified release of active principle
EP2277861A4 (en)	2012-05-02	CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH
IL205313A0 (en)	2010-12-30	Pharmaceutical formulation of clavulanic acid
IL209698A (en)	2016-03-31	Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox
IL194906A0 (en)	2009-08-03	Triphenylmethylphosphonate ester derivatives and pharmaceutical compositions containing the same
IL194094A0 (en)	2009-08-03	Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
AU2007282536B2 (en)	2012-11-22	Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient
ZA201005394B (en)	2014-01-29	15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
SI2219611T1 (sl)	2013-07-31	Farmacevtske oblike za sproĺ äśanje aktivnih spojin
HK1140942A (en)	2010-10-29	Self-precipitating pharmaceutical formulations for the modified release of active principle
GB0610207D0 (en)	2006-07-05	New forms of active pharmaceutical ingredient
EP2016945A4 (en)	2009-07-15	A THIAZONE DERIVATIVE PHARMACEUTICAL ACTIVE SUBSTANCE